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Abstract
Functional Asymmetry of the Immune Cell Plasma Membrane
Eric Malmberg, B.S.
Advisory Professor: Ilya Levental, Ph.D.
Mammalian cells maintain a distinct disparity in lipid composition between the two leaflets of the
bilayer of the plasma membrane. This compositional asymmetry is most prominent for
phosphatidylserine (PS), a negatively charged lipid that is found almost exclusively on the
cytoplasmic (inner) leaflet of the plasma membrane. This energetically unfavorable asymmetry is
maintained by the activity of ATP-dependent transporters called flippases and destroyed by energyindependent lipid channels called scramblases. Although this compositional asymmetry has been
known for decades, there has been little investigation of its structural impact on the physical
properties of the membrane, nor its functional impact in healthy cells. Here, we seek to determine
the effect of compositional asymmetry on the biophysical properties of the plasma membrane and to
determine the function of PS scrambling in the activation of immune cells. Canonically, PS is
exposed to the extracellular (outer) leaflet of the plasma membrane in an irreversible manner when
cells undergo apoptosis, marking them for clearing by macrophages. The primary mediator of PS
exposure in cells (otherwise known as phospholipid scrambling) is a calcium activated chloride
channel protein known as TMEM16F (or Anoctamin 6; Ano6). The scrambling activity of this
channel is gated by intracellular calcium, with increased Ca2+ levels leading to channel opening and
rapid movement of PS from the inner leaflet to the outer. During cell death and platelet activation,
this process is irreversible; however, it has been recently shown that it also occurs in immune cells,
but reversibly. Although such behavior has been observed across many different immune cell types,
so far, no functional role has been attributed to it. Through pharmacological inhibition and genetic
iv

deletion of Ano6, we show that plasma membrane asymmetry may affect calcium mediated cell
signaling in immune cells. This work paves the way for future studies to determine the broad roles of
compositional and biophysical plasma membrane asymmetry in cellular physiology, and the specific
mechanisms by which it is involved in various cell signaling pathways.
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INTRODUCTION
Almost all mammalian cells have a distinct lipid composition between the two leaflets of the
bilayer of the plasma membrane.

This compositional asymmetry

is most prominent

for

phosphatidylserine (PS), a negatively charged lipid that is found almost exclusively on the cytoplasmic
(inner) leaflet of the plasma membrane(Verkleij et al., 1973). This energetically unfavorab le
asymmetry is maintained by the activity of ATP dependent transporters called flippases(Shor et al.,
2016). Canonically, PS is exposed to the extracellular (outer) leaflet of the plasma membrane when
cells undergo apoptosis. This exposure marks dead cells for phagocytosis by macrophages, which
detect the exposed PS on the plasma membrane(Ravichandran, 2010). PS exposure also occurs in
platelets upon activation, where it is an essential component of the clotting cascade; PS exposure is
essential for assembly of fully active prothrombinase complexes(Rosing et al., 1980). This PS
exposure has been shown to be mediated by membrane bound scramblase proteins, such as those in
the anoctamin family or the Xkr family(Nagata et al., 2016). The anoctamin scramblase family
contains 10 members, which carry multiple transmembrane domains(Gyobu et al., 2016). Most are
located at the plasma membrane, where 5 of these family members function as a calcium dependent
phospholipid scramblase(Suzuki et al., 2013). Among the more prominent of these is Anoctamin 6
(Ano6), a recently identified calcium activated chloride channel protein and the primary mediator of
PS exposure in cells(Whitlock and Hartzell, 2017). The scrambling activity of this channel is gated by
intracellular calcium, with increased intracellular calcium levels leading to activation and rapid
movement of PS from the inner leaflet to the outer(Oh and Jung, 2016).

Although it has not been fully demonstrated, this scrambling is not believed to be specific to
PS, but rather most lipids in the PM can redistribute according to their concentration gradients, thus
destroying the asymmetry of the living cell PM. Canonically, this loss of PS asymmetry was believed
1

to be irreversible, occurring during cell death(Nagata et al., 2016) or during platelet activation as an
active component of the clotting cascade(Bevers and Williamson, 2010). However, it has been recently
shown that it also occurs in immune cells in a transient manner(Martin et al., 2000). Here, Ca2+ spikes
induced by immune receptor activation induce transient PS exposure, which is then rectified by the
activity of flippases(Devaux, 1988). Mutations in Ano6 have been shown to be implicated in the rare
congenital bleeding disorder known as Scott Syndrome(Zwaal et al., 2004). This disorder is
characterized by instances of severe and uncontrollable bleeding. Patients exhibiting this syndrome
show platelet cells that are incapable of externalizing PS during the activation of the clotting
cascade(Zwaal et al., 2004). During this cascade, phospholipids and calcium facilitate the binding of
FXa and FIXa to the surface of platelets(Spronk et al., 2014). Because platelet cells in patients with
Scott Syndrome are unable to externalize PS during the activation of this clotting cascade, platelet
cells are unable to bind FXa and FIXa, leading to a cessation in the clotting cascade followed by
uncontrollable bleeding(Rosing et al., 1985). The findings from patients with Scott Syndrome
implicate a potential functional role of PS during periods of intracellular calcium flux, and may offer
new insights into a potential functional role of plasma membrane asymmetry. The loss of this
asymmetry has been shown to occur in a transient manner during periods of normal cell signaling,
such as what occurs during immune cell activation(Segawa et al., 2011).
Although such behavior has been observed across many different immune cell types(Smrž et
al., 2007), and there are indirect indications that PS exposure may be functionally important for
immune cell function, the specific functional roles are not well understood, nor are the cellular
mechanisms affected by PS scrambling in healthy cells. We hypothesize that active PS scrambling
changes the biophysical properties of the plasma membrane, thereby affecting cell signaling
during activation. We addressed this hypothesis through the following aims: 1) to determine the
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effect of PS asymmetry on the biophysical properties of the plasma membrane and 2) to determine the
functional role of PS scrambling during immune cell signaling.
We addressed the effect of PS asymmetry on the biophysical properties of the plasma
membrane using the giant plasma membrane vesicle (GPMV) model system (fig1-A), a novel
technique to isolate and analyze native plasma membranes from intact cells. This method involves
chemically induced blebbing of the membrane away from live cells by a treatment containing
sulfhydryl-reactive chemicals in a calcium-containing buffer. The PM vesicles formed by this
procedure contain the native complexity and diversity of intact cell PMs(Sezgin et al., 2012).
Remarkably, these isolated PMs also phase separate into macroscopic, coexisting liquid domains (Fig
1-A). These domains have different compositions and physical properties, simila r to the coexistence
A

B

of liquid disordered and liquid ordered
domains

in

membranes(Veatch

synthetic

model

and

2003).

Keller,

Although we cannot see large rafts in living
Green = GPI-GFP (raft marker)
Red = unsaturated phospholipid (non-raft)

GPMVs stained with AnxV to label
external PS

Figure 1: GPMVs as a model system to study the
plasma membrane A) GPMVs can partition into liquid
ordered and liquid disordered phases, each of which can
be labeled with raft or non-raft markers. GPMVs are also
useful in studying the biophysical properties of the PM. B)
Unlike native state PMs, PS is externalized during GPMV
formation. This is the most significant limitation to GPMV
as a model system to study the PM

cells, these GPMVs are the best proxy for
studying

this behavior in a biologica l

system. Because of their biological origin,
these intact
complexity

PM vesicles
and

diversity

contain
of

the

native

membrane components, making them an excellent model system to study plasma membrane
biophysical properties. Furthermore, the liquid-liquid phase separation therein provides compelling
evidence for the central tenant of the lipid raft hypothesis(Levental and Levental,

2015).

Methodologically, this model system offers great insights into the biophysical nature of the native
state plasma membrane allowing for the investigation of structural determinants of raft partitioning,
3

protein distribution (liquid order or liquid disorder) and how this partitioning can affect cell
signaling(Sengupta et al., 2008; Simons and Toomre, 2000). GPMVs can also be used to determine
the lipid content of the PM in response to a variety of conditions including growth, temperature, stress,
etc(Burns et al., 2017). However, these GPMVs are not fully representative of the native state of living
plasma membranes, in that PS is externalized in these vesicles, as shown in Figure 1-B. Here, a calcium
dependent phospholipid binding protein, Annexin V (AnxV) was used to label externalized PS during
GPMV formation. This loss of asymmetry is one of the more significant limitations to accurately
studying the various biophysical properties of the natively asymmetric plasma membrane. The method
required for the production of GPMVs requires the use of chemicals that may make the plasma
membrane permeable to ions such as calcium(Keller et al., 2009) (which is required for the production
of GPMVs). We hypothesized that this increase in intracellular calcium during GPMV formatio n
activates the calcium dependent PS scramblase Ano6, thereby actively inducing PS exposure. For the
experiments in Aim 1, we explored ways to produce PS asymmetric GPMVs using a variety of
inhibitor and genetic tools that target the calcium activated scramblase protein, Ano6.
The second aim of this project is to determine the function of PS scrambling during the
activation of immune cell signaling. Although PS scrambling is canonically believed to be an
irreversible process, used as an “eat me” signal to macrophages(Ravichandran, 2010), recent studies
have suggested that in healthy cells, PS externalization is transient and can occur during periods of
intracellular calcium spikes(Smrž et al., 2007). This PS externalization has also been suggested to be
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mediated by the calcium activated chloride channel scramblase, Ano6(Ousingsawat et al., 2015). We
evaluated the functional role of PS asymmetry during immune cell signaling (degranulation, Fig 2),
utilizing rat basophilic leukemia cells (RBLs) as a model system. These cells function similarly to
mast cells, in that they can undergo antigen- mediated exocytosis of intracellular granules(Barsumia n
et al., 1981). Mast cells are part of the innate immune system, which is involved in phagocytic action
and pathogen killing activity(Singh et al., 2016). Mast cells are retained in close vicinity with blood
vessels, which allows them to have a crucial sentinel role in host defense(Marshall, 2004). These cells
contain a variety of functions including regulation of both innate and adaptive immunity(Singh et al.,
2016), tolerance to skin graft rejection(de Vries and Noelle, 2010), among many others. They play a
pivotal role in protective immunity, including the ability to respond to and inactivate venoms, such as
those from a honey-bee and viper(Galli et al., 2016). However, they are also implicated in various
allergic

reactions,

anaphylactic

includ ing

shock(Zhou

et

al.,

2013). The classical form of allergic
reaction

involves

mast

cell

degranulation to release histamines in
response to antigen, leading to the
mobilization
Figure 2: Schematic diagram of the degranulation pathway
in mast cells. Binding of antigen (via IgE) to receptors on the
cell surface activates signaling pathways, resulting in activation
of PKC and release of intracellular calcium, which in turn leads
to exocytosis of histamine-containing granules. The increase in
intracellular calcium may also activate Ano6, which is involved
in the scrambling and externalization of PS. Figure as originally
published with permission from Holowka, D., Wilkes, M.,
Stefan, C., and Baird, B. (2012). Front. Immun.
doi:10.3389/fimmu.2012.00104

of

a

variety

of

inflammatory signals(Theoharides et
al., 2012).
In

mast

cells,

histamine

granule exocytosis is initiated

by

antigen binding and crosslinking IgE,

which is in turn bound to transfer Fc receptors. This crosslinking results in a signaling cascade leading
5

to the mobilization of intracellular calcium, activation of PKC and the release of granules containing
histamines and enzymes(Holowka et al., 2016). We hypothesize that the mobilization of intracellular
calcium during the degranulation process leads to the activation of Ano6, resulting in a loss of PM
asymmetry by externalization of PS. This loss of asymmetry may be functionally important to the
progression of the degranulation pathway, and may affect mast cell function. In order to address this
hypothesis, we investigated PS exposure during Ca2+-mediated signaling and the mechanism for how
lipid scrambling of the PM may affect immune cell activation by targeting a Ca 2+-activated Cl- channel
scramblase protein and evaluated the degranulation efficiency in a mast cell line.

6

RESULTS
Chemical inhibition of scramblase in plasma membranes produces PS-asymmetric GPMVs.
The primary mediator of PS scrambling in healthy cells is a recently identified scramblase
protein Anoctamin 6 (Ano6), a calcium activated chloride channel protein found in nearly all
eukaryotic cells(Martins et al., 2011). It has been found to be necessary and sufficient to mediate
rapid movement of PS from the inner to the outer leaflet of
the PM(Whitlock and Hartzell, 2017). Fig 3 depicts the
proposed mechanism of action of Ano6. Ca2+ binding
causes a conformational change in Ano6, which allows for
flux of Cl- ions and exchange of lipids between the inner
and outer leaflet of the PM. Ano6 can be inhib ited
chemically, using a Ca-activated chloride channel blocker
known

as

A01

(6-(1,1-Dimethylethyl)-2-[(2-

furanylcarbonyl)amino]-4,5,6,7tetrahydrobenzo[b]thiophene-3-carboxylic acid).
In an attempt to produce native PS-asymmetr ic

Figure 3: Schematic of Ano6
mediated PS scrambling. Ca2+ binding
opens a cavity that allows the exchange
of ions and phospholipids between
leaflets. Figure as originally published
with permission from Oh, U., and Jung,
J. (2016). Eur. J. Physiol. doi:
10.1007/s00424-016-1790-0

GPMVs, 150uM A01 was added to the GPMV production
buffer and PS exposure to the outer leaflet was measured using binding of a fluorescently tagged
Annexin V (tagged with Alexa568; AnxV-568). While control GPMVs clearly and strongly bound
AnxV-568, A01 treatment produced GPMVs that did not show obvious AnxV binding (not shown),
suggesting that PS remained on the internal leaflet. Because such microscopic assays are difficult to
–
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Figure 4: A01 inhibits PS exposure in GPMVs. Flow cytometry data of (A) unlabeled GPMVs (i.e.
background fluorescence); (B) control GPMVs labeled with AnxV show high AnxV binding to nearly
all vesicles, revealing externalization of PS; (C) GPMVs produced in the presence of A01. A01
successfully inhibits PS externalization during GPMV formation .

quantitate and do in high-throughput, we verified that A01 GPMVs were PS-asymmetric by using
flow cytometry to measure AnxV568 binding (Fig. 4). Vesicles produced in the presence of A01 show
minimal AnxV binding, indicating a lack of exposed PS, verifying PS-asymmetric GPMVs.

Untreated

A01

A01 prior to GPMV isolation

Having produced PS-asymmetric GPMVs, we next sought
to answer our central question of whether lipid asymmetry affected

A
PM physical
A01 after GPMV isolation

B

properties.

Specifically,

we assayed

whether

asymmetry affects domain formation by analyzing phase separation
of vesicles produced with A01. GPMVs produced with A01 showed
a dramatic reduction in phase separation compared to untreated

Figure 5: A01inhibits phase
separation in GPMVs A)
GPMVs isolated using
standard conditions show
macroscopic phase separation
below ~15oC. A01 inhibits
phase separation when added
during GPMV isolation B) A01
inhibits phase separation
when added after GPMV
isolation

vesicles. At temperatures as low as 2 o C, there was no observable
phase separation in GPMVs produced with A01, in contrast to
control GPMVs, where phase separation could be observed as high
as 15o C (Fig 5-A). This observation suggested that PS asymmetr y
had a major effect on phase separation in isolated PMs, essentially

completely suppressing phase separation. However, we needed to control for a possible non-specific
effect of the A01 compound itself, rather than its effect on asymmetry. To that end, we added A01 to
8

GPMVs after isolation, which should not have any effect on PS asymmetry, which had been lost during
isolation in the absence of drug. This treatment also resulted in a wholesale abolition of phase
separation, similar to addition of A01 prior to GPMV isolation, despite having no effect on PS
asymmetry (Fig 5-B). These observations revealed that A01 directly impacts membrane biophysica l
properties independent of its effect on PS asymmetry. To separate the
Control

A01

direct effects of A01 from its effects on PS asymmetry, we attempted
several means to wash out the drug after isolation of PS asymmetr ic
GPMVs. The protocol for monitoring efficiency of wash-out was as
follows: A01 was added to GPMVs (final concentration 50uM), which
lead to a loss of phase separation observed via fluorescence microscopy
Control

A01

A

at 10o C. We hypothesized that
successful removal of A01 from
GPMVs would produce a return

B

Figure 7: Failure to remove A01
from GPMVs. A) GPMVs dialyzed
overnight at 4oC in GPMV buffer
containing Bio-Beads. No return of
phase separation suggested failure
to remove the drug. B) An excess
of synthetic SUVs was added to
GPMVs after production in an
attempt to dilute A01. There was no
return of phase separation in these
GPMVs.

Figure 6: Dialysis of
GPMVs after addition
of A01. A01 was added
to GPMVs after
production and isolation,
followed by dialysis in
GPMV buffer overnight at
4C. There was no return
of phase separation in
GPMVs after this
dialysis.

of microscopically observable phase separation.

The first attempt to wash-out A01 was by dialys is.
Vesicles were dialyzed in GPMV buffer (150mM NaCl, 2mM
CaCl2 , 10mM HEPES pH7.4) for 2hr, 4hr or overnight at 4C.
None of these protocols produced an observable return of phase
separation after dialysis (Fig 6). We then attempted to wash-out
A01 using Bio-Beads, which are designed to remove detergents

and other lipophilic materials from solutions. GPMVs treated with A01 were dialyzed in a solution
containing these beads for 2hr, 4hr or overnight at 4C. Again, there was no observable phase separation
in GPMVs dialyzed with Bio-Beads (Fig 7A). Finally, we tried incubating with small unilame llar
9

vesicles (SUVs) to remove A01 from GPMVs. Since A01 is slightly lipophilic, we hypothesized that
it was incorporating into membranes non-specifically, though not necessarily irreversibly. Thus, we
reasoned that SUVs would provide a large pool of membranes, thereby effectively diluting the drug
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Figure 8: GPMVs produced from Ano6 knockdown are PS asymmetric. A) Flow cytometry showing
AnxV binding to control GPMVs, indicating externalization of PS. B) Although siRNA 1 was unable to
knockdown Ano6, C-D) a large subset of GPMVs prepared after siRNA knockdown of Ano6 with siRNA 2
and 3 did not bind AnxV, thus remained PS-asymmetric. Data obtained by Barbara Diaz-Rohrer

from the GPMVs. Unfortunately, as in all other wash-out experiments, we did not observe a recovery
of phase separation, leading us to abandon these attempts to remove A01 from GPMVs (Fig 7B).

siRNA knockdown of scramblase protein Ano6 to produce PS asymmetric GPMVs.
Although the chemical inhibition of Ano6 produced PS asymmetric GPMVs, A01 dramatica lly
affected phase separation independent of its effect on PS asymmetry. Thus, this artifact prevented
analysis of the biophysical properties of PS asymmetric membranes using A01 for isolation. To
overcome this limitation, we attempted to produce asymmetric GPMVs by removing, rather than
inhibiting, Ano6. The first step was to determine if removing Ano6 in cells would result in the
10

production of PS asymmetric GPMVs. To this end, we used siRNA targeting Ano6 in Rat Basophilic
Leukemia (RBL) cells to knock down the levels of this protein and test the effect of PS asymmetry in
isolated GPMVs. Cells were transfected with one of three siRNA sequences targeting Ano6, or a
combination of all three. 2 days after transfection, GPMVs were produced from these cells, and
external PS was labeled using AnxV, which was quantified by flow cytometry. Fig 8 indicates that all
siRNA treatments resulted in the production of a subset of GPMVs that appeared to have PS remaining
internal. Most notably, sequences 2 and 3 (see materials) lead to near-complete abolition of PS
Stimulated

externalization.

PS External

PS Internal

PS External

PS Internal

Unstimulated

A

RBLs is a promising direction for
of

PS

asymmetr ic

GPMVs.

PS External

PS Internal

PS External

PS Internal

results

confirm that targeting of Ano6 in

production

B

These

PS External

PS Internal

PS External

C

PS Internal

Knockout of Ano6 in RBLs
using CRISPR/Cas9 produces
cells which do not externalize PS
during ionomycin mediated
AnxV Binding

AnxV Binding

Figure 9: Flow cytometry of RBL cells transfected with
CRISPR plasmids targeting Ano6. Plasmids contain two
different gRNA sequences (labeled Cas9-1 or Cas9-2
respectively), followed by treatment with ionomycin and AnxV568 to label external PS. A) Cells transfected with an empty Cas9
plasmid robustly externalized PS upon treatment with 5uM
ionomycin (5min; 37C). B-C) Cells transfected with CRISPR
plasmids targeting Ano6 showed clear increases in the number of
cells that did not externalize PS upon calcium flux mediated by
ionomycin.

calcium stimulation.
Although siRNA treatment
was successful in producing PS
asymmetric GPMVs RBLs have a
very low transfection rate (~30%).
We determined that producing a
complete Ano6 knockout cell line
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would allow for more consistent results during each experiment, removing the potential error of
transfection inefficiency. To produce an Ano6 KO cell line with RBLs, we utilized the CRISPR/Cas9
system, targeting exon 6 of Ano6. Two gRNA sequences were used and cells transfected with the
CRISPR plasmid (PX458). In order to show that knockout of Ano6 using CRISPR/Cas9 was
successful in inhibiting PS externalization, PS externalization during ionomycin- mediated calcium
stimulation was analyzed using flow cytometry. Ionomycin is an ionophore, used to raise the levels of
intracellular levels of calcium. Fig 9 shows that CRISPR targeting of Ano6 was successful in
producing a population of cells that do not externalize PS during ionomycin mediated calcium
stimulation (as shown by a lack of AnxV binding).
After verifying that the CRISPR targeting of Ano6
lead to the expected/desired phenotype (no externalization of
PS during calcium flux induced by ionomycin), another
batch of cells were transfected and sorted using fluoresce nce
activated cell sorting (FACS). These cells were bulk sorted
for expression of the CRISPR plasmid, which contained a

GFPExpression
expression
GFP
Figure 10: Sorting of RBL cells
based on GFP expression. The
CRISPR/Cas9 plasmid used contains
a GFP reporter gene, which is used to
show successful transfection into a
cell. Cells expressing GFP were kept,
while the cells not expressing GFP
were discarded

reporter GFP (Fig 10). After recovery, cells were treated
with ionomycin, external PS was labeled with AnxV, and
AnxV binding was analyzed via flow cytometry, showing a
large percentage of cells with an Ano6 KO phenotype (i.e.
not exposing PS upon ionomycin treatment) (Fig11A).
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While this approach was successful in generating cells, which did not expose PS upon calcium
stimulation, it did not produce a pure population of such cells. We initially presumed this was because
not all transfected (i.e. GFP-positive) cells produced an effective CRISPR knockout. To isolate only
those cells which did not expose PS, the GFP-sorted population from Fig 11A cells were further sorted
by FACS using the desired phenotype of minimal ionomycin-stimulated AnxV binding. After
recovery, these sorted cells were analyzed using ionomycin and AnxV binding to determine if this
protocol produced a pure population of cells that failed to externalize PS. Surprisingly, as shown in
Fig11B, while the phenotype-directed sorting yielded a large population of cells that did not
externalize PS upon ionomycin mediated calcium stimulation, it was far from complete (~50%). Even
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Figure 11: CRISPR targeting of Ano6 produces RBLs that do not externalize PS during
ionomycin mediated calcium stimulation, but not stable lines. (A) Flow cytometry analysis of AnxV
binding (i.e. PS exposure) following ionomycin stimulation in RBL cells sorted by GFP expression after
transfecting with CRISPR plasmid targeting Ano6. This protocol produced a significant – though
incomplete – population of cells that did not externalize PS. B) Cells that did not externalize PS were
further sorted, based on lack of AnxV568 binding upon ionomycin mediated calcium stimulation. After
sorting, this population of cells was further analyzed for ionomycin-mediated PS exposure. The
proportion of cells that did not externalize PS increased notably, but still not nearly to 100%. C) Two
days after the analysis in B, the population of cells that did not externalize PS upon ionomycin mediated
calcium stimulation decreased dramatically and D) essentially disappeared four days after the initial
sort.
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more surprisingly, two days after this initial analysis, the population of cells that did not externalize
PS dramatically decreased (Fig 11C), and four days after the initial analysis this population of cells
had nearly completely disappeared (Fig 11-D). This disappearance of the AnxV-negative population
suggested that these cells were at a growth disadvantage compared to the WT RBLs.
To prevent Ano6 KO cells from being at a growth disadvantage compared to the WT RBLs,
single cell cloning of CRISPR/Cas9 Ano6 KO cells was also attempted. Using FACS, single cells
expressing GFP (an indicator of successful CRISPR transfection) were sorted into individual wells of
a 96-well dish. After sufficient colony expansion, we sequenced the genomic region targeting Ano6
to determine if clonal colonies were genetically modified by CRISPR/Cas9. All single-cell clones that
grew into large colonies had the wild type Ano6 sequence, indicating no CRISPR-mediated
modification. However, there were a number of wells that remained single cells for one month; the
cell was healthy but did not divide. This single cell cloning was attempted multiple times, using both
gRNA sequences, by multiple experimenters, all with the same results. From this set of observations,
we concluded that Ano6 may be an essential gene for cell division in RBLs, and therefore that stable
knockouts cannot be produced. RBLs may not have been the optimal choice for producing an Ano6
KO cell line, as they may be lacking in other anoctamin family members, which may be required for
cell survival(Suzuki et al., 2013). Moving forward, we switched to using a new cell line to produce an
Ano6 knockout in HeLa.
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Development of Ano6 KO HeLa cell line.
Due to the insuperable hurdles encountered in our attempts to develop an Ano6 KO cell line
in RBLs, we switched our focus to developing an Ano6 KO cell line in HeLa cells. These cells were
selected in part due

Original Sequence
to the ease of

HeLa KO 4
HeLa KO 1

transfecting
compared to RBLs
(20-30% efficiency
in RBLs) and also

Figure 12: CRISPR/Cas9 targeting of Ano6 in HeLa produced two Ano6 KO
clones. Genomic DNA of HeLa clonal colonies produced by transfecting the
parental cells with a CRISPR/Cas9 plasmid targeting Ano6. Clone KO4
contained a single base-pair insertion, while clone KO1 contain an insertiondeletion mutation. Both are non-sense mutations expected to lead to protein
knockout.

because they may
express other Ano6 family members that could support cell survival in the absence of Ano6. HeLa
cells were treated exactly like RBLs – i.e. transfected using the same CRISPR/Cas9 plasmid, but
containing an established gRNA sequence targeting exon 6 in Ano6 (see methods). For this attempt,
WT

KO1

KO4

Ano6

we did not attempt to establish a bulksorted population, but rather tried

GAPDH

immediately for single-cell clones.

Figure 13: Western Blot of Ano6 in HeLa Ano6 KO
clones. Ano6 is not produced in either HeLa KO clone,
as indicated by Western Blot analysis.

Genomic DNA from these clones was
sequenced to determine whether Ano6

KO was successful. Two clones were identified which showed frame-shift mutations - one a single
base pair insertion (KO4) and the other containing an insertion-deletion (KO1) (Fig 12). Knockout
was next validated using Western Blotting (Fig 13) indicating that both knockouts were not
producing the Ano6 protein and flow cytometry (Fig 14). For flow cytometry analysis, WT and KO
cells were treated with ionomycin to increase intracellular calcium levels, activate Ano6, and induce
PS scrambling. This flow cytometry data supports the genetic and Western blotting evidence,
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Figure 14: Ano6 knockout HeLa clones do not externalize PS upon
ionomycin mediated calcium stimulation. A) Unstimulated HeLa cells do not
externalize PS. B) Ionomycin treatment results in robust PS externalization in WT
HeLa cells. C) KO1 and D) KO4 clones contained large populations of cells with
impaired PS externalization, as expected from Ano6 knockout. Although the
majority of cells are AnxV-negative, there is a small population of AnxV-positive
cells. These could be residual WT cells remaining from the cloning procedure, or
knockouts that externalize PS by other mechanisms.

externalize PS
upon ionomycin
mediated calcium
stimulation. There
also appears to be
a population of

HeLa’s that do externalize PS. These could be residual WT cells remaining from the cloning
procedure, or knockouts that externalize PS by other mechanisms.
Isolation of GPMVs from Ano6 KO cells.
Having verified successful knock-out of Ano6 in HeLa, and that these cells exhibited the
expected phenotype during ionomycin mediated calcium stimulation (lack of PS externalization), we
sought to isolate GPMVs from these cells. The rationale being that since these cells are resistant to PS
scrambling upon calcium influx, their GPMVs would remain asymmetric. GPMVs were produced
using standard protocols (specifically the PFA/DTT isolation), and external PS was labeled using
fluorescent AnxV. AnxV binding was quantified in fluorescent images by drawing line-scans through
each vesicle in ImageJ. The fold intensity over background fluorescence was then used as a semiquantitative readout of AnxV binding for each vesicle.
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Figure 15: AnxV labeling of GPMVs produced from HeLa Ano6 KO cells.
A) GPMVs produced from WT HeLa cells and Ano6 KO lines in the presence
of 2mM calcium. A01 treatment of cells prior to GPMV isolation leads to a
significant decrease in AnxV binding, as expected (see Fig 3A). While both
KOs showed slightly reduced AnxV binding compared to WT, the effects were
highly variable and not statistically significant. B) Similar results were
observed in vesicles prepared using 200 µM Ca 2+ for GPMV isolation. The
only notable difference was that A01 slightly increased AnxV binding, which
was an unexpected and unexplained observation. Error bars: Standard error
of mean

A01 (150uM) was used
as a positive control for
impaired

PS

externalization / AnxV
binding. Although there

appeared to be a decrease in AnxV binding in Ano6 knockout clones compared to WT, there was
significant experiment-to-experiment variability. In two experiments (out of ten), the result was
perfect – i.e. no measurable AnxV binding to GPMVs from clones, robust binding in WTs. However,
in the other experiments, the results were less robust, with occasional experiments showing no
difference at all between WT and KOs (Fig 15-A). Ultimately, statistical analysis of all experime nts
showed no low p-values (WT and KO1 p=0.2418, WT and KO4 p=0.8366) and therefore no confident
statistical statement could be made about the difference between the groups. To date, we have been
unable to find the source of this experimental variability, and therefore currently cannot consistently
produce asymmetric GPMVs.
Ca2+ levels were altered during GPMV formation.
To explain these observations, we hypothesized that the large concentration of Ca2+ (2mM)
used in GPMV isolation may be responsible for activation of other potential Ca2+-activated scramblase
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proteins within the cell. To address this, we determined the minimum concentration of Ca2+ that could
be sufficient to produce an appropriate number of GPMVs, and determined this value to be ~200 M.
We produced GPMVs with this lower calcium level and analyzed in the same manner as described
above. Unfortunately, the overall variability of AnxV binding was not reduced and there was still not
significant difference between the groups (Fig15-B WT and KO1 p=0.1099, WT and KO4 p=0.1723).
It is surprising to note that AnxV binding in the positive control group (WT + A01) appear to be much
greater than the negative control (WT). We currently do not have an explanation for this effect.
Nevertheless, these results indicate that lower concentrations of Ca 2+ during GPMV formation, in
either WT HeLa or Ano6 knockouts, did not yield PS asymmetric GPMVs.

There are other TMEM16 (Anoctamin) scramblase proteins that may be involved in PS
scrambling during GPMV formation.
It is possible that the inability of HeLa Ano6 knockouts to produce PS asymmetric GPMVs
may be the result of scramblase activity from other anoctamin family proteins not expressed in RBLs.
There is a total of 9 additional Anoctamin proteins in eukaryotic cells, 5 of which have been shown to
exhibit scramblase activity(Suzuki et al., 2013). In tissues associated with immunity, it was shown that
the only Anoctamin scramblase protein expressed is Ano6 (TMEM16F). However, in ovary and
uterine tissues, Ano6 is the most abundantly expressed scramblase protein, but others are present as
well, namely Ano4 and Ano9 (TMEM16D and J, respectively). If true in HeLa, the presence of these
scramblase proteins (Ano4, Ano9) may be compensating for the loss of Ano6 in HeLa KOs, resulting
in the loss of PS asymmetry during GPMV formation.
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Caspase-3 is activated during GPMV formation.
There are also other non-TMEM scramblase proteins, one of which is Xkr8 (XK related 8
protein), and it is activated by apoptosis(Suzuki et al., 2014). Active caspase-3 has been shown to
activate this protein in response to apoptotic stimuli, and the mechanism of scrambling is independent
of Ca2+ induced PS exposure by the TMEM family members. We postulated that GPMV formation is
leading to the activation of apoptotic pathways in cells, specifically the activation of caspase-3.
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Figure 16: Percentage of HeLa cells with active
caspase following a variety of treatments. Cells
were treated with camptothecin as a positive control to
induce apoptosis, or with GPMV buffer for 45min at
37C, followed by labeling with a caspase 3/7 detection
reagent. These results indicate that apoptotic
caspases are being activated during GPMV formation,
which potentially activates Xkr8.

GPMV isolatio n

conditions (37o C for 45 min). After this
incubation period, caspase-3 activation was
detected

by addition

of a caspase-3/7

detection dye (see methods). This dye is

cleaved only by active caspase-3 and 7, resulting in the release of a fluorescently tagged molecule that
binds to nuclear DNA, such that cells with active caspase-3 present with brightly fluorescent nuclei.
Results from these experiments (Fig. 16) indicate that production of GPMVs using NEM or DTT/PFA
in a calcium containing buffer results in the activation of caspase-3/7, to a level even above
camptothecin. The activation of caspase-3 during GPMV formation suggests a mechanism by which
PS may be externalized in Ano6 KO HeLa cells, i.e. via activation of the apoptotic scramblase protein
Xkr8.
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Z-DEVD-fmk was used to prevent caspase-3 activation.
To prevent the activation of caspase-3 during GPMV formation (and potentially prevent
activation of PS scramblase Xkr8), we attempted to use Z-DEVD-fmk, a known irreversible inhib itor
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Figure 17: Z-DEVD-fmk does not inhibit
caspase-3 during GPMV formation. Cells
were treated with 10µM camptothecin as a
positive control to induce apoptosis or with
GPMV buffer for 45min at 37C followed by
labeling with a caspase 3/7 detection
reagent. Cells were pre-treated with ZDEVD-fmk, which was present in all buffers
throughout each experiment. Z-DEVD-fmk
was successful in inhibiting caspase-3
activation in CPT treated cells. However, it
was unable to prevent caspase-3 activation
during GPMV formation with DTT/PFA.

detection dye (Thermo). Surprisingly, although ZDEVD-fmk is capable of preventing activation of
caspase-3 in the camptothecin control, it is unable to
prevent caspase-3 activation during GPMV formatio n
with DTT/PFA (Fig 17). Inhibition of caspase-3 was
attempted during NEM mediated GPMV formatio n,
with similar results as observed in DTT/PFA produced

GPMVs, i.e. no effect of the inhibitor on caspase-3 activation (not shown).
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Aim 2: Measuring the effect of PS asymmetry on mast cell activation (degranulation).
The next aim of this project was to determine the effect of PS asymmetry and its transient loss
on immune cell signaling, specifically on mast cell activation and degranulation. Here, we will
evaluate the functional role of PS asymmetry during this process of degranulation. Mast cell activatio n
involves the binding of antigen to FcRI receptors on the mast cell surface, activating a variety of
signaling pathways that result in PKC activation and mobilization of intracellular calcium. These steps
ultimately lead to the exocytosis of histamine containing granules (Fig 2). Another consequence of the
mobilization of intracellular calcium is activation of Ano6, resulting in the externalization of PS(Oh
and Jung, 2016). We hypothesized that this PS externalization may be an important component of cell
signaling, and therefore that inhibition of PS
scrambling

during

antigen-mediated

signa ling

would affect mast cell activation and secretion
efficiency. To test this, RBL cells (a leukemic mast
cell line) were activated in the presence of the Ca2+Control

A01

Unstimulated

Control

A01

DNP-BSA
stimulated

Control

A01

activated chloride channel / scramblase inhib itor

PMA/Ionomycin

Figure 18: Scramblase inhibitor (A01)
abrogates antigen mediated secretion.
Stimulation with antigen increases granule
exocytosis (estimated from beta-hexaminidase
secretion to ~40% from 20% in unstimulated
cells. Treatment of cells with A01 (a scramblase
inhibitor) completely abrogated antigenmediated secretion with no effect on basal
secretion or secretion induced by PMA and
ionomycin, which bypass antigen mediated
signaling to directly activate secretion. This
finding indicates that PS externalization (via
Ano6) is required for pathways upstream from
PKC in order to mediate degranulation.

A01. Secretion efficiency was determined

by

measuring beta-hexaminidase (which resides in
histamine

granules)

in the secreted medium

relative to the same enzyme (beta-hex) remaining
in the cells. As a positive control, PMA and
ionomycin

were used to bypass the antigen

mediated steps in this pathway, by increasing PKC
activation and calcium levels directly. Fig18 shows

that the scramblase inhibitor A01 abrogates antigen mediated secretion in mast cells. Basal levels of
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secretion for both A01 treated and untreated cells was ~20%. Stimulation with antigen increased
secretion to ~40%, whereas antigen stimulation in the presence of A01 resulted in no increase in
secretion compared to basal. These results suggest that A01 is capable of abrogating antigen mediated
stimulation, possibly through inhibition of Ano6 activation and PS externalization. The control results
suggest that PS scrambling is necessary for activation of PKC and other upstream pathways, and that
secretion is not affected when antigen mediated simulation is bypassed. However, it will be important
to verify that A01 is preventing the externalization of PS.
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Figure 19: A01 inhibits PS scrambling in activated mast cells:
Measurement of PS externalization (measured by AnxV binding) in mast
cells (RBL) upon antigen mediated activation and degranulation. After
5min, PS externalization appears to maximize in the control group. Over
the course of the next 10 minutes, PS begins to re-internalize, as
measured by a decrease in AnxV binding from 5 to 15min. When cells
are treated with A01 prior to and during antigen mediated stimulation, we
see a very small increase in externalized PS, but not to the same levels
as observed in the untreated control groups, and is not followed by any
marked decrease in externalized PS up to 30min.

cells were

activated for varying times
(1, 5, 10, 15 and 30 min) in
the presence or absence of
A01 and external PS was
labeled with AnxV after

fixing. AnxV binding was measured using a Tecan plate reader. Figure 19 shows that A01 does inhib it
PS externalization in activated mast cells. This data lends credence to the possibility that PS
externalization is required for antigen mediated mast cell activation, and inhibition using A01 results
in an overall decrease in secretion efficiency of beta-hex.
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Charge-based interaction of proteins with the electronegative inner leaflet of the PM.
Our previous results suggest calcium- mediated PS scrambling may be an important component
of mast cell signaling and activation. To explain the potential mechanism by which this effect might
be occurring, we hypothesized that scrambling of PS changes the electrostatic charge of the inner
leaflet of the PM, regulating protein localization. We investigated this hypothesis by investigating the
effects

of

PS

scrambling

on

the

localization of LactC2 (the PS binding

B

A

fragment of the lacthedrin protein) and KRas(Lee et al., 2012; Zhou et al., 2014,
PS PS PS

2015, 2017), which has been shown to
have

a strong

interaction

with

-- -- -+- +- -+- -

LactC2

the

KRas

negatively charged inner leaflet of the
plasma membrane(Gelabert-Baldrich

et

al., 2014) (Fig 20). WT or Ano6 KO HeLa
cells were transfected with either GFP
labeled LactC2 or K-Ras and subjected to

Figure 20: Representation of interaction of LactC2
and K-Ras with the negatively charged PS in the
plasma membrane . A) LactC2 is a section of the
lactadherin protein that specifically binds to PS in the
plasma membrane. B) K-Ras contains a post translational
modification that allows for binding to the negatively
charged lipids within the inner leaflet of the plasma
membrane

ionomycin- mediated calcium stimulation to induce PS scrambling. In WT cells, ionomycin resulted
in the relocalization of both LactC2 and K-Ras from the PM to intracellular compartments, includ ing
the Golgi and ER, as identified by the morphology of the staining. In Ano6 KOs, both LactC2 and K Ras remain largely PM bound following ionomycin stimulation (Fig 21-22). Binding of LactC2 and
K-Ras to the PM was quantified by comparing the fluorescence intensity of the PM of transfected cells
to the intracellular fluorescence using images captured before and during ionomycin mediated Ca 2+
stimulation (Fig 23). In both control groups, PM bound LactC2 and K-Ras are rapidly re-localized
during ionomycin mediated Ca2+ stimulation. However, in both Ano6 KO groups, the overall trend
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indicates that LactC2 and K-Ras remain
mostly

PM bound

during

Untreated

mediated Ca2+ stimulation. These results
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D
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K-Ras during ionomycin mediated calcium
stimulation is due to the change of the

B
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ionomyc in

Ionomycin

KO

electronegative inner leaflet of the PM and
/ or a decrease in the concentration of inner
leaflet PS. As the concentration of interna l
PS decreases, LactC2 and K-Ras may be
mislocalizing from an area of low PS
concentration (cytosolic PM leaflet), to an
area of higher PS concentration (i.e. Golgi

Figure 21: Relocalization of LactC2 in HeLa cells
during ionomycin mediated calcium stimulation. A)
Cells transfected with plasmids for GFP labeled LactC2
show this protein preferentially localizing to the plasma
membrane of the cells B) During inomycin mediated
calcium stimulation of WT HeLa cells, LactC2 is shown
to relocalize from the membrane to intracellular
components such as the Golgi and ER. C) As in WT
cells, LactC2 is preferentially localized to the PM in Ano6
KO resting cells but D) during ionomcyin mediated
calcium stimulation, PS is not scrambled and LactC2
remains mostly bound to the plasma membrane

and ER). These results also suggest a mechanism by which certain cellular pathways may be regulated
by PS scrambling. This relocalization may be important in functioning as a negative regulator of
various signaling pathways within cells, specifically those involving Ca 2+ signaling. For example, KRas that is PM bound is typically in its active form(van der Hoeven et al., 2013; Schmick et al., 2014).
One of the consequences of active K-Ras signaling

is the mobilization

of intracellular

calcium(Fujimoto et al., 2011). This mobilization of intracellular Ca2+ may result in the activation of
Ano6, scrambling of PS, and the relocalization of K-Ras, shutting down the pathway. More research
will be needed to determine if the activity of this pathway is affected by the loss of PS asymmetry.
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Figure 22: Mislocalization of K-Ras in HeLa cells during
ionomycin mediated calcium stimulation. A) Cells
transfected with plasmids for GFP labeled K-Ras show this
protein preferentially localizing to the plasma membrane of the
cells B) During inomycin mediated calcium stimulation of WT
HeLa cells, K-Ras is shown to mislocalize from the membrane
to intracellular components such as the Golgi and ER. C) As in
WT cells, K-Ras is preferentially localized to the PM in Ano6 KO
resting cells but D) during ionomcyin mediated calcium
stimulation, PS is not scrambled and K-Ras remains mostly
bound to the plasma membrane
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Figure 23: K-Ras and LactC2 remain PM bound in Ano6 KO HeLa during Ca 2+ stimulation. A) In
both Ano6 KO clones (inhibition of PS scrambling), PM binding of LactC2 remains mostly unchanged
during ionomycin mediated Ca2+ stimulation, whereas LactC2 relocalization in control cells occurs rapidly
(within 5 min following stimulation). This effect is more prominent in cells expressing with K -Ras (B) which
is not re-localized and remains mostly PM bound in both Ano6 KO clones compared to control cel ls.
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DISCUSSION
To study the biophysical properties of the plasma membrane (PM), we utilize a method
which involves the chemical isolation of PM vesicles (known as Giant Plasma Membrane Vesicles;
GPMVs) induced by NEM or PFA/DTT in a Ca2+ containing buffer. These GPMVs provide a simple
model system to study the biophysical properties of the plasma membrane, including lipid
distribution between leaflets, lipid packing, as well as the separation of the plasma membrane into
coexisting liquid phases. Currently, this model system is the most representative system for studying
the biophysical properties of the isolated plasma membrane; however, it is not fully representative of
the native state of the PM in living cells. GPMVs that are produced from cells lose the native lipid
leaflet asymmetry normally found in living cells. We can show this lack of strict lipid asymmetry in
GPMVs by utilizing Annexin V (AnxV) as a marker for externally-exposed phosphatidylserine (PS).
In live cells, PS is found almost exclusively on the inner (cytoplasmic) leaflet of the plasma
membrane bilayer. In contrast, in isolated GPMVs, PS is externalized. It has been shown that GPMV
inducing reagents such as DTT/PFA induce a constant Ca2+ influx(Keller et al., 2009). This constant
Ca2+ flux may be responsible for the activation of the Ca2+ activated chloride channel scramblase
Anoctamin 6 (Ano6) resulting in the externalization of PS during GPMV formation. Studies have
shown that inhibition or knockdown of Ano6 results in an inability of cells to externalize PS during
Ca2+ mediated cell signaling(Ousingsawat et al., 2015). We hypothesized that targeting of Ano6
would result in the production of cells that do not externalize PS during Ca 2+ mediated GPMV
formation. We first sought to inhibit the PS scrambling protein Ano6 through utilization of a Ca2+
activated Cl- channel inhibiting drug, A01.
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Chemical inhibition of scramblase produces PS asymmetric GPMVs, but abrogates phase
separation.
Our initial results had shown that targeting of the Ca 2+ activated chloride channel scramblase
Ano6 in RBLs (via chemical inhibition with A01) is capable of producing PS asymmetric GPMVs.
We used a Ca2+ activated chloride channel inhibitor, A01, to successfully inhibit the scramblase,
which yielded PS asymmetric GPMVs as evidenced by a lack of AnxV568 binding (see Fig 3). We
next analyzed the biophysical properties of these PS-asymmetric GPMVs, and observed a dramatic
change in the appearance / stability of Lo/Ld phase separation. Specifically, phase separation was
not observable in GPMVs produced with A01, even at temperatures as low as 2 o C. Typical
temperatures at which phase separation is first observable in GPMVs produced from RBLs are
~15o C.
Initially, this was an exciting result, as it appeared that lipid asymmetry was dramatically
affecting biophysical properties of the PM bilayer, with asymmetric vesicles being unable to phase
separate while PS-scrambled ones did. Unfortunately, we then noted that the addition of A01 to
GPMVs after production (when asymmetry is already lost), at the same concentrations used for
inhibition of scrambling, also lowered phase separation temperatures and led to a complete
abrogation of phase separation in these GPMVs. Thus, the effect of the drug alone on isolated PMs
was essentially equivalent to the effect of the drug on cells during GPMV isolation, suggesting that
the observed biophysical effects were more likely the result of a non-specific interaction(s) of the
drug with the membrane, rather than a specific effect of PS asymmetry.
We next attempted a number of methods to remove A01 from isolated asymmetric GPMVs
and thereby remove the biophysical effects of this drug and measure any possible effects of
asymmetry. To verify that A01 was being successfully removed, we used phase separation in
GPMVs as a read-out: after GPMVs were isolated, A01 was added at concentrations that were
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shown to completely abrogate phase separation (50µM). These GPMVs were next dialyzed for 2, 4
or 24hrs in GPMV buffer and observed to determine if phase separation had returned, which would
be evidence that the drug was removed. Dialysis was shown to be unsuccessful in removing A01, as
we observed no return on phase separation. We next attempted to remove A01 from GPMVs using
adsorbent Bio-Beads. These Bio-Beads are designed to remove lipophilic compounds and detergents
from solutions. As with dialysis, there was no observable return of phase separation to these
GPMVs, and we concluded that this method was unsuccessful in removing A01. Finally, we
attempted to remove A01 by utilizing small unilamellar vesicles (SUVs). We hypothesized that
SUVs would add a large pool of membranes, thereby effectively diluting the drug from the GPMVs.
However, like the previous attempts to remove A01, this method also proved unsuccessful, as
addition of SUVs to GPMVs treated with A01 showed no return of phase separation.

Genetically targeting the Ca2+ activated chloride channel Ano6.
Although the Ca2+ activated Cl- channel inhibitor A01 was shown to successfully inhibit PS
externalization during GPMV formation in RBLs, likely through targeting of Ano6, we were unable
to examine the biophysical properties of GPMVs produced with A01, because of the artefactual
behavior of this drug. Since we were unable to remove this drug from GPMVs after production, we
changed tracks to test whether we could produce PS-asymmetric GPMVs by genetically targeting
the Ca2+ activated Cl- channel scramblase Ano6. siRNA knockdown of Ano6 resulted in the
production of PS asymmetric GPMVs, as shown through AnxV labeling and flow analysis of AnxV
binding to GPMVs. These results suggest that eliminating the Ca 2+ Cl- channel scramblase Ano6 was
sufficient for the production of a cell line capable of maintaining PS asymmetry during GPMV
formation.
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Since knockdown of Ano6 in RBLs resulted in the production of PS asymmetric GPMVs, we
decided that the next step should be to produce a stable Ano6 knockout cell line, as these would
presumably be more repeatable and robust, because of the absolute lack of this protein. Further, we
could then use these lines for molecular/cell biology analyses of the effect of PS-asymmetry (and the
loss thereof) on various signaling pathways. To produce this knockout cell line, we utilized the
CRISPR/Cas9 system, which creates a double strand break at a specified target sequence on the
genome, resulting in the activation of the non-homologous end joining repair pathway. We
determined if these plasmids would produce a population of RBL cells which did not externalize PS
during calcium mediated stimulation. Ca2+ stimulation was mediated using ionomycin, followed by
labeling of external PS using AnxV568 and quantification by flow cytometry. Transfection of RBLs
with CRISPR plasmids containing either gRNA-1 or gRNA-2 were successful in producing cells that
did not externalize PS during ionomycin mediated calcium stimulation. Cells were next sorted, based
on this lack of AnxV568 binding (thus no PS externalization), using fluorescence activated cell
sorting (FACS). After sorting, the population of cells that did not externalize PS increased from
~20% to ~50% pre-to post sorting, respectively. We initially expected this population of cells that do
not externalize PS to be 100% and not 50%. It is possible that during this sorting process, a
population of WT cells which did not externalize PS during ionomycin mediated Ca 2+ stimulation,
for an unknown reason, were sorted along with our Ano6 KO cells. However, two days after the
initial ionomycin mediated Ca2+ stimulation assay, when it was performed again, we observed a very
rapid decrease in the number of cells that did not externalize PS compared to previous results. 4 days
after the initial assay, the population of cells that did not externalize PS had completely disappeared.
This transfecting and sorting process was repeated, with the same results. Based on these results, we
hypothesized that targeting of Ano6 for knockout resulted in the production of a population of cells
that was being out-competed for growth compared to WT cells due to this phenotypic change.
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In order to circumvent the potential growth competition between Ano6 WT and Ano6 KO
RBLs, cells were transfected and clonally selected. Single cells which expressed GFP (as an
indication of successful transfection of CRISPR plasmid) were sorted (using FACS) into a 96-well
dish containing conditioned RBL growth medium (equal volumes of RBL growth medium
supplemented with culture medium partially used by cells). Once colonies expanded sufficiently,
genomic analysis was performed on each of the recovered clones. Only six of the 96-wells
successfully grew up into colonies and genomic analysis of these clones revealed that they had a WT
genotype. In some wells, however, we observed single cells which did not divide after more than a
month. Single cell sorting was performed 3 different times by three different experimenters, all with
the same results – namely growth of only WT cells (as determined by genomic analysis). Therefore,
we concluded that our protocol for producing Ano6 knockouts were leading to cell lethality, either
because Ano6 is an essential gene in RBLs or because of off target effects.

Development of Ano6 KO in HeLa using CRISPR.
To overcome this limitation of Ano6 KO lethality in RBLs, we next switched to developing
an Ano6 KO cell line from HeLa cells, as these cells are easier to transfect than RBLs and also from
a completely different tissue source (endometrial versus hematopoietic). Single cell cloning revealed
that, in contrast to RBLs, most of the HeLa wells grew into stable colonies. Genomic analysis
revealed that two of the three colonies analyzed showed alterations to the target genome site: one
showing a single base pair insertion and the other showing an insertion / deletion mutation. We
verified that these lines were knockouts by Western blotting, which showed an absence of Ano6 in
both KO clones compared to the WT. Similarly, PS externalization during ionomycin- mediated Ca2+
stimulation was analyzed using AnxV568, revealing a significant population of clonally selected
cells which did not externalize PS during ionomycin stimulation; similar to RBLs when Ano6 was
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knocked down or inhibited (see Fig3,7). Thus, we successfully produced Ano6 knockout cell lines
that had the desired phenotype of failing to expose PS during Ca 2+ stimulation.

Isolation of GPMVs from HeLa Ano6 KO Clones.
After verification that Ano6 was successfully knocked out, we produced GPMVs from both
Ano6 KO cell lines (termed KO1 and KO4) to determine if they would be PS-asymmetric. Although
there was a small decrease in the overall fluorescence intensity in AnxV568 binding in Ano6 KO1
and KO4 cells compared to the WT HeLa cells, these differences were not statistically significant
(see Fig 14). Surprisingly, two of 10 experiments produced exactly the expected/desired results;
minimal AnxV568 binding (thus no PS externalization) in KO1 and KO4 compared to robust AnxV
binding to WT GPMVs. However, this effect was not repeatable and we were unable to find the
source of this variation. We speculate that this variatio n may be due to the presence of other
scramblases or Anoctamin family proteins in HeLa that are not present in RBLs.
We postulated that alternative scramblase proteins to Ano6 may be activated by the process
of GPMV formation, and identified as likely candidates either (1) other Anoctamin family proteins;
or (2) Xkr8, a protein shown to exhibit caspase-3 dependent scramblase activity during
apoptosis(Suzuki et al., 2014). Focusing first on Xkr8, we determined whether GPMV formation
resulted in the activation of caspase-3. Since Xkr8 is a caspase-3 dependent PS scramblase,
activation of caspase-3 would likely result in subsequent activation of Xkr8 and scrambling of PS
during GPMV formation. This would potentially explain the externalization of PS observed during
GPMV formation in Ano6 KO HeLa cells and shed some light on the process by which GPMVs are
formed. Our results indicated that caspase-3 was indeed being activated during GPMV formation
with either NEM and DTT/PFA. It is unusual that NEM based GPMV production results in the
activation of caspase-3, as NEM is very specific in targeting thiols, and is commonly used to modify
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and target cysteine residues, therefore it should act as an inhibitor or caspase-3. We then
hypothesized that blocking caspase-3 activity during GPMV formation may inhibit Xkr8 activation
and therefore PS scrambling. We attempted to inhibit caspase-3 activity with the widely-used small
molecule Z-DEVD-fmk. This drug is considered relatively selective for caspase-3 among
others(Garcia-Calvo et al., 1998). Surprisingly, Z-DEVD-fmk was unable to prevent the activation
of caspase-3 during GPMV formation. We are unsure why this drug was unsuccessful in preventing
caspase-3 activation, especially when GPMVs are isolated with NEM. Since caspase-3 is a member
of the cysteine-aspartic acid protease family, and its active site contains a cysteine residue, the
presence of NEM should directly inhibit caspase-3 activation in HeLa. Thus, there should not be any
interaction between NEM and Z-DEVD-fmk, as there are no cysteine residues on Z-DEVD-fmk.
Currently, it is unclear why Z-DEVD-fmk is not efficiently inhibiting caspase-3 during GPMV
isolation. It is worth noting here that this drug was capable of inhibiting caspase-3 activation in
control conditions (camptothecin-induced apoptosis).

Future directions: targeting other scramblase proteins in HeLa to produce PS asymmetric
GPMVs.
Since we were unable to prevent caspase-3 activation during GPMV formation in HeLa with
a caspase-3 inhibiting drug, the next step would be to target Xkr8 directly for either knockdown or
knockout. Future experiments should also focus on the targeted knockout or knockdown of other
scramblases found in these cells. Specifically, Suzuki et al 2013 showed expression of two additional
anoctamin scramblases, Ano4 and Ano9 in mouse ovarian and uterine tissues, and these proteins
exhibit PS scrambling activity during Ca2+ stimulation34 . It may be that these two proteins are
compensating for the loss of Ano6, resulting in the scrambling of PS during GPMV formation.
Notably, it was shown that mouse tissues involved in immunity expressed only a single PS
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scrambling anoctamin, i.e. Ano6. If the same is true for RBLs, it may be postulated that the only
protein responsible for scrambling of PS during Ca 2+ mediated signaling in these cells is Ano6. This
could serve to explain why siRNA targeted knockdown of Ano6 worked so well in RBLs, but
knocking out Ano6 in HeLa did not work, in that other anoctamin scramblases are expressed in
HeLa which are capable of compensating for the loss of Ano6, but there are no other anoctamin
scramblases expressed in RBLs. This could also explain why RBL Ano6 KO clones were unable to
divide, and why we observed such a large decrease in the population of Ano6 KO cells over time;
Ano6 (and thus Ca2+ mediated scrambling) may be essential for normal cellular functions, such as
cytokinesis. If this is true, then the presence of other Ca2+ mediated scrambling proteins (Ano4 and
Ano6) in HeLa may be compensating for the loss of Ano6, resulting in viable clones, but also
externalization of PS during GPMV formation. To test these hypotheses, and towards the ultimate
goal of producing PS-asymmetric GPMVs, we have now developed multiplexed CRISPR plasmids
to target Ano6, Ano4, Ano9 and Xkr8 in human cells. Multiplexing CRISPR plasmids involves the
insertion of two independent gRNA sequences onto a single CRISPR backbone. This allows for the
production of two Cas9 proteins, targeting two different regions of the target genome, resulting in
two double strand breaks in the DNA and removal of multiple exons within a gene. This method will
allow for more efficient screening to determine which combination of gene knockouts will be most
effective in producing PS asymmetric GPMVs. The next steps will be the transfection of HeLa or
HEK cells with various combinations of these plasmids, followed by qPCR to determine knock-out
efficiency. Next GPMVs will be produced and asymmetry assayed as above. Once we establish a
combination of gene knockouts that produce PS asymmetric GPMVs, we can begin to analyze their
biophysical properties including phase separation, membrane diffusivity, etc.
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Aim 2: Measuring the effect of PS asymmetry, by chemical inhibition of Ano6 on mast cell
activation (degranulation).
The second aspect of this project was to determine the functional role of PS asymmetry, and
its transient loss, on the activation of immune cells. To this end, we measured the effect of PS
asymmetry on antigen- induced activation of mast cells. Specifically, a mast cell line (rat basophilic
leukemia; RBL) can be induced to activate by treatment with IgE antibodies and their cognate,
oligomeric antigens. Upon activation, these cells secrete a variety of inflammatory mediators (e.g.
histamine and serotonin), but also the secretory granule enzyme beta-hexosaminidase. The activity
of this enzyme can be quantified using standard protocols and gives a robust proxy for the efficiency
of activation/degranulation. We compared secreted beta-hex between untreated cells, and those in
which scrambling was inhibited, to determine the effect of PS-asymmetry on the degranulation
process. If PS scrambling is important for mast cell activation, we expected to observe differences
in the efficiency of secretion of beta-hex in cells there were unable to properly scramble PS.

Because we were unable to develop a stable Ano6 KO RBL line, we utilized A01 to prevent
PS externalization during degranulation in RBLs. The degranulation process involves several steps,
beginning with the binding of IgE-bound antigen to the FceRI receptor, followed by the initiation of
downstream signaling, most notably the mobilization of intracellular Ca2+ and activation of PKC,
leading to eventual granule secretion. We showed that during the degranulation process, PS is
rapidly externalized on RBLs (as measured by AnxV568 binding) followed by a slower return to
basal levels of external PS (Fig 19) This suggests that the Ca2+ fluxes present during RBL signaling
also induce the activation of Ano6, resulting in the externalization of PS. When cells were stimulated
to degranulate in the presence of A01, we showed that PS was not externalized during the
degranulation process, as expected if we effectively inhibited PS scrambling activity (presumably of
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Ano6). Remarkably, this inhibition of PS externalization during degranulation resulted in a decrease
in the secretion efficiency of beta-hex. Notably, we also observed that secretion mediated by our
positive control, i.e. treatment with ionomycin and PMA, was not affected by A01. PMA and
ionomycin activate PKC and increase intracellular Ca 2+ respectively, bypassing the antigen binding
step. These results indicate that PS scrambling may be important in the initial steps of degranulation,
and that preventing this PS scrambling may thus inhibit other downstream signaling effects. This
could indicate a mechanism by which certain pathways within the cell are regulated by PS
externalization. For example, this degranulation process may be negatively regulated by increases of
intracellular Ca2+. Once intracellular Ca2+ reaches a high enough concentration for a long enough
period of time (as a consequence of the mobilization of Ca2+ during degranulation), PS may be
scrambled via Ano6, leading to a re-localization of membrane bound proteins, ultimately “turning
off” the degranulation pathway. This potential regulatory mechanism may be utilized by multiple
pathways involving intracellular Ca2+ signaling, serving as an “off switch” for a variety of pathways.

Effect of PS scrambling on charged proteins which interact with the electronegative inner
leaflet of the PM.
To elucidate the mechanism by which inhibiting PS scrambling could affect cell signaling,
we used the HeLa Ano6 KO cell lines, transfecting them with plasmids coding for GFP labeled
LactC2 and K-Ras(Lee et al., 2012; Zhou et al., 2014, 2015, 2017). We hypothesized that
ionomycin- mediated Ca2+ stimulation would lead to scrambling of PS via Ano6 in WT cells,
resulting in a re-localization of both LactC2 and K-Ras, whereas in Ano6 KOs we would not observe
this re-localization. LactC2 is the PS binding portion of the lactahedrin protein, while the C-terminal
region of K-Ras interacts with the strong electronegative charge of the inner leaflet of the PM. Both
of these proteins are located primarily at the inner leaflet of the plasma membrane in unstimulated
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cells. When PS scrambling was induced through ionomycin mediated Ca 2+ stimulation in WT HeLa,
both LactC2 and K-Ras re-localized from the PM to intracellular compartments of the cell (Fig 2122), including the Golgi and ER as identified by the morphology of the staining. We hypothesize that
this re-localization is occurring due to the externalization of PS during Ca2+ flux, resulting in a
change in the electronegative inner leaflet, and decrease in the concentration of PS, causing both
LactC2 and K-Ras to translocate from an area of lower PS concentration (scrambled PM) to areas
containing higher concentration of PS (cytoplasmic leaflets of other organelles). This inference is
supported by the observations that when Ano6 KO cells were subjected to ionomycin mediated Ca 2+
stimulation, both LactC2 and K-Ras remained largely PM bound. Thus, failure to scramble PS
inhibits relocalization of a PS sensor (LactC2) and a charge sensor (K-Ras) from the PM during cell
activation. These results may indicate a mechanism whereby certain cellular pathways are regulated
by PS scrambling. Since active K-Ras interacts with its upstream regulators and downstream
effectors at the PM, is it possible that increases in intracellular Ca 2+ downstream of immune receptor
engagement result in the activation of Ano6 (and/or other scramblase proteins), causing
externalization of PS and leading to re-localization and deactivation of K-Ras. Future experiments to
determine this will include comparing K-Ras signaling in Ano6 KOs compared to WT cells.
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MATERIALS and METHODS
Cell culture.
RBL cells were cultured in medium containing 60% MEM, 30% RPMI medium, 10% FBS, 2mM
glutamine, 100units/mL penicillin and 100µg/mL streptomycin at 37o C in humidified 5% CO 2 . HeLa
cells were cultured in medium containing 90% EMEM, 10% FBS, 2mM glutamine, 100units/mL
penicillin and 100µg/mL streptomycin at 37o C in humidified 5% CO 2 .

GPMV Isolation, Labeling, Treatment and Analysis.
GPMVs were isolated and imaged under temperature controlled conditions(Sezgin et al., 2012). For
post-isolation treatments, isolation chemicals were removed by dialysis in GPMV buffer (150mM
NaCl, 2mM CaCl2 , 10mM HEPES pH 7.4). For GPMVs dialyzed with Bio-Beads (Bio-Rad),
GPMVs were placed in dialysis tubing (ThermoFishser 10K molecular weight cutoff) and placed in
a solution of GPMV buffer containing 0.1g/mL Bio-Beads and left at 4o C for 2, 4 or 24hrs prior to
analysis. In order to produce PS asymmetric GPMVs through chemical inhibition of Ano6, using a
calcium activated chloride channel inhibitor, A01 (6-(1,1-Dimethylethyl)-2-[(2furanylcarbonyl)amino]-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid: CalBiochem) was
added to GPMV buffer at a concentration of 150µM.

Analysis of AnxV Binding to GPMVs.
External PS was labeled using AnxV Alexa Fluor 568 (AnxV568) on GPMVs during the production
process. Stock solutions of AnxV568 (ThermoFisher catalog: A13202) were diluted 1:100 in GPMV
buffer prior to addition to cells to produce GPMVs. GPMVs were labeled with Fast DiO
(ThermoFisher), a nonspecific membrane binding green fluorescent dye. This dye was used as a
positive control to confirm that GPMVs were successfully produced. After production, GPMVs were
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collected and imaged using fluorescence microscopy. Vesicles were first visualized via Fast DiO
staining, then the same vesicles were imaged for AnxV568 binding. Images were analyzed in
ImageJ: a line was drawn through each GPMV labeled with Fast DiO. Then an intensity scan was
made in the AnxV568 channel, with the fluorescence intensity of each vesicle compared to that of
the background in each image. Data was represented as the fold intensity of AnxV568 fluorescence
to background.

Ano6 siRNA Knockdown and Analysis of Ano6 in RBLs.
Silencer Select® siRNA targeting rat Ano6 was purchased from ThermoFisher (catalog number
4390771, Assay ID: s163856, s163857, s163858). Three sequences were available and purchased.
For transfection, RBLs were trypsinized, resuspended in RBL culture medium, and centrifuged at
300xg for 5min. Medium was removed, and ~1e6 cells resuspended in 100uL Mirus Buffer
containing 15uL of either siRNA 1, 2, 3 or a mixture (5uL of each sequence). Cells were transfected
with siRNA by electroporation at 960 Ohms and 320V for ~14msec. After 48-72hrs of recovery,
GPMVs were produced from cells and external PS was labeled as above. Flow cytometry (BD LSR
Fortessa Cell Analyzer System) was used to analyze AnxV568 binding to external PS in GPMVs.
Unlabeled GPMVs were used to set the threshold for AnxV-negative vesicles, while GPMVs
produced from WT cells (labeled with AnxV568) were used to define the maximum for AnxV568
binding.

Development of CRISPR/Cas9 Plasmids.
Plasmids were obtained from Addgene. Empty CRISPR/Cas9 plasmid was purchased from
Addgene. The plasmid used was designated pSpCas9(BB)-2A-GFP (PX458) and contains a single
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cloning backbone for sgRNA and a GFP reporter gene. The target sequences (see below) were
cloned into the empty backbone using the Zhang Lab protocol(Ran et al., 2013). The sense sequence
of the gRNA contained the 5’CACCGNNNNNNNNNNNNNNNNNNNN3’ format (oligo 1), while
the antisense sequence contained the 5’CNNNNNNNNNNNNNNNNNNNNCAAA3’ format (oligo
2). Oligos were annealed in the following manner: 1µL of oligo 1 (100µM), 1µL oligo 2 (100µM),
1uL 10X T4 ligation Buffer (NEB), 6.5µL ddH2 O, 0.5µL T4 PNK (NEB) final volume 10uL. Oligos
were annealed in a thermocycler (Bio-Rad) using the following parameters: 37 o C 30 min, 95o C 5
min, then ramp down to 25o C at 5o C/min. The annealed strand was ligated into the empty backbone
using T4 DNA ligase with protocol provided by manufacturer. For ligation, using a thermocycler:
37o C 5min, 25o C 5min, repeat 6-12 times. E. coli DH5α cells were transformed with this
digested/ligated product in the following manner: Thaw cells on ice 30min, add 2µL digested/ligated
product to 50µL cells and place back on ice 10min. Remove from ice, incubate at 42 o C for 60sec.
Add 450µL pre-warmed SOC medium to bacteria/DNA and incubate at 37o C, 300RPM for 1hr. Add
100uL bacteria to an LB agar plate (100µM Ampicillin) and spread. Incubate at 37 o C overnight. The
next day, pick colonies from dish, and grow in LB medium containing 100µM ampicillin overnight
at 37o C, 250RPM. Isolate plasmids using the Qiagen mini-prep plasmid isolation kit following
established instructions.

CRISPR/Cas9 gRNA Plasmids, Transfection and Clonal Selection in RBLs
For Ano6 KO in RBLs
gRNA sequence 1: CACCGACTCGCTCTTTTTCACCGATGG
gRNA sequence 2: CACCGTACGAAGACGAGAGCAAGAAGG
Both sequences were designed to target exon 2 in the Ano6 gene. RBLs were transfected in the same
manner as above (siRNA knockdown). 2ug of CRISPR/Cas9 plasmid were used for transfection.
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24hrs after transfection, cells were sorted by MD Anderson Flow Cytometry Core and selected for
GFP expression. For genomic analysis of the region targeted by gRNA 1 or gRNA2, genomic DNA
was isolated using the NucleoSpin® Tissue Kit (Macherey-Nagel) following manufacturer’s
protocol. After isolation, PCR amplification was performed on the genomic region targeted by the
CRISPR/Cas9 plasmid.
PCR forward primer: TCCTGCACAAGCATTCTAGGCTACT
PCR reverse primer: TGCTCTGCACATACAAAGTGTAATCCC
After amplification, the PCR product was sequenced by GeneWiz using the PCR forward and PCR
reverse primers listed above.

Bulk Sorting of CRISPR/Cas9 Transfected (Ano6 KO) RBLs.
48hrs after transfection of RBLs with CRISPR/Cas9 targeting Ano6, cells were sorted based on lack
of AnxV568 binding using Flow Activated Cell Sorting (FACS) at the MD Anderson Flow
Cytometry Core. Cells were incubated with 5µM ionomycin in Tyrode’s buffer (containing a 1:100
diluted AnxV568) at 37o C for 5min. Cells were then FACS-sorted, keeping only cells that did not
bind AnxV568 (thresholds for binding set as above). These sorted cells were cultured for at least 7
days to allow recovery after sorting prior to further analysis.

Flow Cytometry Analysis of Ano6 KO RBLs.
RBL cells were trypsinized, resuspended in RBL culture medium, and centrifuged. After this,
medium was removed and cells resuspended in Tyrode’s Buffer (135mM NaCl, 5mM KCl, 1.8mM
CaCl2 , 1mM MgCl2 , 5.6mM glucose, 20mM HEPES pH 7.4). PS externalization was measured
using flow cytometry to monitor the extent of binding of AnxV568 to external PS in intact live cells
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(BD LSR Fortessa Cell Analyzer Systems). PS externalization was mediated by addition of
ionomycin (Sigma Aldrich, 5µM final concentration) and incubation at 37 o C for 5min.

CRISPR/Cas9 gRNA Plasmids, Transfection and Clonal Selection in HeLa’s.
For Ano6 KO in HeLa’s, the gRNA sequence used was obtained from Horizon Discovery. gRNA
sequence: TGTAAAAGTACACGCACCAT. HeLa cells were transfected with 2µg PX458 plasmid
containing aforementioned gRNA sequence (as a control, unmodified PX458 plasmid) using
Lipofectamine® 3000 (ThermoFisher) following the manufacturer’s protocol with the following
modification: cells were trypsinized, and resuspended in culture medium. Next, medium was
removed, and cells re-suspended in a mixture of Lipofectamine® 3000 and DNA for 2min at room
temperature. After this incubation, cells were placed on to multi-well plates containing culture
medium. 24hrs after transfection, ~95% of all remaining cells were GFP+. For clonal selection, cells
were counted and diluted to ½ cell per 100µL medium and placed onto a 96-well dish. After 1-week,
wells that contained a single colony were selected for further expansion. Once these colonies had
grown sufficiently, genomic DNA was isolated using the NucleoSpin® Tissue Kit (MachereyNagel). After isolation, PCR amplification was performed on the genomic region targeted by the
CRISPR/Cas9 plasmid. Primer sequences used were obtained from Horizon Discovery. PCR
forward primer: ATCTTCACTTTTAGTGGTGGTCTCT
PCR reverse primer: GGTAAACCAGTTGAGTGTACCAAAG
After amplification, PCR product was sequenced (Gene-Wiz) using the forward primer for
sequencing.
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Western Blot of Ano6.
Anti-Ano6 polyclonal antibody (N-terminus probing region: PA5-35240) was purchased from
ThermoFisher. Cells were grown to confluency in a 6-well dish. Cells were washed on ice (with icecold PBS) 2x, followed by lysis in 100µL RIPA buffer (150mM NaCl, 1% Triton X-100, 0.1% SDS,
0.5% sodium deoxycholate, 50mM Tris pH 8.0) containing fresh DTT (100uM) and 1x proteinase
inhibitor cocktail (PIC). Cells were homogenized with a 24G needle 15x and kept on ice 20min,
followed by centrifugation at 12,000RPM at 4 o C for 15min. Protein concentration was measured
using BCA kit (Thermo Scientific). 50µg cell extract was loaded onto an 8% SDS gel and run at 80V
until the dye reached the bottom of the separating gel. Transfer to PVDF membrane at 125mA,
90min with 2x transfer buffer containing 0.05% SDS. Block membrane 1hr room temperature (RT)
in 5% non-fat milk (NFM) dissolved in Tris-Buffered Saline with 0.1% Tween-20 TBST. Probe
overnight at 4o C with anti-Ano6 antibody (1:500 dilution from stock) in 1% NFM and TBST. Wash
membrane 3 times for 10 minutes in TBST. Probe with anti-rabbit HRP antibody (SIGMA Genosys)
in 3% NFM and TBST 2hrs RT. Wash membrane 3 times for 10min in TBST. Incubate in ECL
solution (Bio-Rad) 10min RT and image using ChemiDoc (Bio-Rad).

Detection of Caspase-3/7.
To detect caspase-3/7 activation, HeLa cells were grown to confluency in a 96-well dish, followed
by treatment with either 10µM camptothecin (Cayman Chemical Company) as a positive control
(8hrs 37C in HeLa culture medium) to induce caspase3/7 activation or GPMV buffer containing
2mM NEM or 2mM DTT/25mM PFA for 45min at 37 o C (to mimic conditions for GPMV
production). After appropriate incubation times, cells were washed 2x with 1X PBS. Active caspase3/7 was detected using CellEventT M Caspase-3/7 Green Detection Reagent (ThermoFisher catalog:
C10723); reagent was diluted to 7.5µM in 1X PBS containing 5% FBS at 37o C for at least 30min.
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After this incubation time, cells were imaged with bright-field overlaid with GFP (bright green
nuclei were considered to have active caspase-3/7). Caspase activation was calculated as a percent of
cells with GFP labeled nuclei relative to the total number of cells.

Inhibition of Caspase-3/7 Activation.
Caspase-3/7 activation was inhibited using Z-DEVD-fmk purchased from Cayman Chemical
Company. A 100mM stock solution in DMSO was prepared from powder. Cells were pre-treated for
1hr at 37o C in HeLa culture medium with Z-DEVD-fmk (100µM). After this pre-treatment, cells
were treated with either camptothecin (10µM 8hrs 37o C) in culture medium containing 100µM ZDEVD-fmk or GPMV buffer containing 2mM NEM or 2mM DTT/25mM PFA 45min 37o C. After
this treatment, active caspase-3/7 was detected as above.

Degranulation of RBLs.
RBLs were plated such that they were 60-80% confluent in a 12-well dish the day the degranulation
assay is to be performed. Cells were kept in serum free RBL culture medium overnight. Cells were
sensitized for 1hr 37o C with 1.0µg/mL anit-dinitrophenol (DNP) IgE in complete RBL culture
medium. Excess IgE was removed before stimulation by washing cells 3x with 1X PBS and once
with Tyrode’s buffer containing 1mg/mL BSA. To stimulate, 1µg/mL DNP-BSA (dinitrophenolbovine serum albumin) was added and the cells were incubated at 37 o C for 30min.

Percent secretion is measured by determining the percent of beta-hexaminidase(beta-hex) secreted as
follows. Following incubation, the supernatant was removed from the cells and saved for further
analysis. The cells were then lysed cells with 1% Triton X-100 (volume equivalent to buffer volume
used during stimulation) for 5min at 37 o C. This lysate and the supernatant above were then used to
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measure the beta-hex levels in remaining and secreted fractions, respectively. To measure beta-hex,
20µL of sample (either lysate or supernatant) was combined with 80µL of 0.375mM 4methylumbelliferyl N-acetyl-beta-D-glucosamine (dissolved in citrate buffer: 49.5mL of 0.05M
citric acid and 50.5mL of 0.05M tri-sodium citrate pH 4.5) for 1hr at 37o C. The reaction was
quenched by addition of 200µL of 0.05M sodium carbonate buffer (60mL of 0.05M Na 2 CO3 and
40mL of 0.05M NaHCO 3 ). The fluorescence was read using Tecan plate reader: Excitation 362,
emission 448. Data was presented as percent beta-hex secreted after averaging a triplicate from each
well. For cells treated with A01, drug was added to stimulation buffer to a final concentration of
150µM.

Detection of External PS on Activated RBLs.
RBLs were activated (as described above) for various time points: 1, 5, 15 and 30min. After
appropriate incubation times, cells were fixed with 4% PFA for 5min on ice, followed by incubation
at room temperature for 25min. Quench reaction with 100mM glycine 2x15min at RT. 1:100 dilution
(in Tyrode’s buffer) of AnxV568 (ThermoFisher catalog: A13202) was added to each well and
incubated for 5min at RT. Fluorescence intensity was obtained using the Tecan plate reader. The
average fluorescence intensity for each well was used for final analysis, normalizing to the
fluorescence intensity of the unstimulated cells.
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